Salvage chemotherapy with temozolomide in primary CNS lymphomas: Preliminary results of a phase II trial

European Journal of Cancer

Volumn 40, Issue 11, 2004, Pages 1682-1688

  Reni, Michele ^a   Mason, Warren ^b   Zaja, Francesco ^c   Perry, James ^d   Franceschi, Enrico ^e   Bernardi, Daniele ^f   Dell'Oro, Stefania ^a   Stelitano, Caterina ^g   Candela, Marco ^h   Abbadessa, Antonio ⁱ   Pace, Andrea ^j   Bordonaro, Roberto ^k   Latte, Giancarlo ^l   Villa, Eugenio ^a   Ferreri, Andrés J M ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY HOSPITAL OF UDINE   (Italy)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^e BELLARIA HOSPITAL   (Italy)

^f CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^g Division of Haematology   (Italy)

^h Torrette Hospital   (Italy)

ⁱ SECOND UNIVERSITY OF NAPLES   (Italy)

^j REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^k San Luigi S Currò Hospital   (Italy)

^l SAN FRANCESCO HOSPITAL   (Italy)

more..

Author keywords

Phase II trial; Primary CNS lymphoma; Salvage therapy; Temozolomide

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; LOMUSTINE; METHOTREXATE; PREDNISONE; PROCARBAZINE; SEDATIVE AGENT; TEMOZOLOMIDE; TENIPOSIDE; THIOTEPA; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE DURATION; DRUG MEGADOSE; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALE; MALNUTRITION; METABOLIC DISORDER; NAUSEA; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; SEROLOGY; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CENTRAL NERVOUS SYSTEM DISEASES; DACARBAZINE; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 3142598712     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.03.008     Document Type: Article

References (23)

1. Abrey L.E., DeAngelis L.M., Yahalom J. Long term survival in primary CNS lymphoma. J. Clin. Oncol. 16:1998;859-863
2. O'Brien P., Roos D., Pratt G., et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J. Clin. Oncol. 18(3):2000;19-526
3. Brada M., Hjiyiannakis D., Hines F., et al. Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL). Int. J. Radiat. Oncol. Biol. Phys. 40(5):1998;1157-1162
4. Ferreri A.J.M., Reni M., Villa E. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann. Oncol. 11:2000;927-937
5. Maher E.A., Fine H.A. Primary CNS lymphoma. Semin. Oncol. 26:1999;346-356
6. Ferreri A.J.M., Reni M., Pasini F., et al. International Extranodal Lymphoma Study Group. A multicenter study of treatment of primary CNS lymphoma. Neurology. 58:2002;1513-1520
7. Reni M., Ferreri A.J.M., Garancini M.P., Villa E. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann. Oncol. 8:1997;227-234
8. Herrlinger U., Schabet M., Brugger W., et al. German Cancer Society Neuro-Oncology Working Group NOA-03. Multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann. Neurol. 51:2002;247-252
9. Guha-Thakurta N., Damek D., Pollack C., et al. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J. Neurooncol. 43:1999;259-268
10. Batchelor T.T., Carson K., O'Neill A., et al. The treatment of primary central nervous system lymphoma (PCNSL) with methotrexate and deferred radiotherapy NABTT 96-07. J. Clin. Oncol. 21:2003;1044-1049
11. Blay J.-.Y., Bouhour D., Carrie C., et al. The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression. Blood. 86(8):1995;2922-2929
12. Glass J., Shustik C., Hochberg F.H., et al. Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD). J. Neurooncol. 30(3):1996;257-265
13. Bessell E.M., Graus F., Punt J.A., et al. Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy. J. Clin. Oncol. 14(3):1996;945-954
14. DeAngelis L., Yahalom J., Thaler H.T., et al. Combined modality therapy for primary CNS lymphoma. J. Clin. Oncol. 10:1992;635-643
15. Wedge S.R., Porteons J.K., Newlands E.S. Temozolomide: A candidate for combination with loco-regional radiotherapy. Br. J. Cancer. 73(suppl 26):1996;43
16. Herrlinger U., Kuker W., Platten M., et al. First-line therapy with temozolomide induces regression of primary CNS lymphoma. Neurology. 58:2002;1573-1574
17. Lerro K.A., Lacy J. Case report: a patient with primary CNS lymphoma treated with temozolomide to complete response. J. Neurooncol. 59(2):2002;165-168
18. Reni M., Ferreri A.J., Landoni C., Villa E. Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J. Natl. Cancer Inst. 92(7):2000;575-576
19. MacDonald D.R., Cascino T.L., Schold S.C. Jr., et al. Response criteria for phase II studies of supratentorial malignant gliomas. J. Clin. Oncol. 8(7):1990;1277-1280
20. Simon R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials. 10:1989;1-10
21. Arellano-Rodrigo E., Lopez-Guillermo A., Bessell E.M., et al. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur. J. Haematol. 70:2003;219-224
22. Tyson R.M., Siegal T., Doolittle N.D., et al. Current status and future of relapsed primary central nervous system lymphoma (PCNSL). Leuk. Lymphoma. 44(4):2003;627-633
23. Korfel A, Fischer L, Thiel E, et al. Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan. Proc Am Soc Clin Oncol 2003, 22, 429